Free tool
FAERS Monitor: Kybella
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206333 or its brand name (Kybella, Deoxycholic Acid). Reports on generic versions are filed under their own applications.
Reports
2,334
Serious
189
8% of reports
Hospitalization
51
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective327
- injection site swelling305
- off label use287
- swelling262
- injection site pain191
- facial paresis130
- injection site nodule123
- nerve injury115
- hypoaesthesia110
- injection site mass104
- injection site induration86
- contusion85
- pain82
- injection site bruising76
- condition aggravated74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 39 |
| 2016 | 354 |
| 2017 | 212 |
| 2018 | 392 |
| 2019 | 314 |
| 2020 | 219 |
| 2021 | 219 |
| 2022 | 203 |
| 2023 | 208 |
| 2024 | 71 |
| 2025 | 73 |
| 2026 | 27 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| facial paresisSignal | 130 | 343.7 | 289.8 | 42,463 |
| injection site noduleSignal | 123 | 101.8 | 85.7 | 12,052 |
| nerve injurySignal | 115 | 94.2 | 78.7 | 10,404 |
| injection site indurationSignal | 86 | 60.2 | 48.9 | 4,916 |
| injection site swellingSignal | 305 | 36.0 | 32.4 | 10,343 |
| injection site massSignal | 104 | 25.4 | 21.1 | 2,412 |
| swellingSignal | 262 | 25.3 | 22.6 | 6,100 |
| injection site bruisingSignal | 76 | 8.6 | 6.9 | 504 |
| contusionSignal | 85 | 8.0 | 6.5 | 512 |
| hypoaesthesiaSignal | 110 | 6.6 | 5.5 | 523 |
| injection site painSignal | 191 | 5.6 | 4.9 | 730 |
| off label useSignal | 287 | 3.0 | 2.7 | 385 |
| drug ineffectiveSignal | 327 | 2.2 | 2.0 | 237 |
| condition aggravatedSignal | 74 | 2.2 | 1.8 | 48 |
| pain | 82 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.